AnaptysBio's Rosnilimab Shows 'Best-in-Disease' Profile in Phase 2b RA Trial
On June 3, AnaptysBio Inc.
Anaptysbio Inc (ANAB)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | EcoR1 Capital Oleg Nodelman | 7,880,094 | $241,288,478 | 11.58% | |
| 2. | Point72 Asset Management Steve Cohen | 2,265,528 | $69,370,467 | -9% | 0.12% |
| 3. | Millennium Management Israel Englander | 1,519,230 | $46,518,823 | +647% | 0.02% |
| 4. | Tang Capital Management Kevin C. Tang | 1,333,639 | $40,836,026 | +1% | 1.57% |
| 5. | Palo Alto Investors William Leland Edwards | 673,520 | $20,623,182 | -18% | 3.82% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $12.95 | 6,646 | $86,069.69 | 7,880,094 | 2025-01-02 | Filing | |
| $12.93 | 13,268 | $171,512.78 | 7,873,448 | 2024-12-31 | Filing | |
| $12.92 | 65,184 | $842,059.95 | 7,860,180 | 2024-12-30 | Filing | |
| $36.50 | 273,972 | $9,999,978.00 | 7,794,996 | 2024-08-14 | Filing | |
| $23.25 | 165,000 | $3,835,755.00 | 7,520,424 | 2021-05-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $48.85 | 1,710 | $83,531.79 | 9,930 | 2026-01-15 | Filing | |
| $48.12 | 9,290 | $446,999.50 | 11,640 | 2026-01-15 | Filing | |
| $44.71 | 3,650 | $163,191.50 | 42,088 | 2026-01-08 | Filing | |
| $44.71 | 2,515 | $112,445.65 | 21,852 | 2026-01-08 | Filing | |
| $44.71 | 2,210 | $98,809.10 | 12,835 | 2026-01-08 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,544,037 | $74,854,914 | 0% | |
| 2. | 70,032 | $3,395,152 | 0% | |
| 3. | 22,560 | $1,093,709 | 0.08% | |
| 4. | 9,286 | $450,185 | 0% | |
| 5. | 7,512 | $364,182 | 0.03% |
News See All
11 Unstoppable Growth Stocks to Invest in Now
BlackRock highlighted that the trade conflict between the US and China continues to cause major economic disruptions.
13 Best Short Squeeze Stocks To Buy Now
In this piece, we will take a look at the 13 best short squeeze stocks to buy now.
AnaptysBio, Inc. (ANAB): Hedge Funds Are Snapping Up
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don't make them change their opinion towards a...
AnaptysBio, Inc. (ANAB): Hedge Funds Are Snapping Up
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios.
10 Best Biotech Stocks to Buy According to Alan Frazier's Frazier Healthcare Partners
In this article, we discuss the 10 best biotech stocks to buy according to Alan Frazier.
Hedge Funds Cashed Out Of AnaptysBio, Inc. (ANAB) Too Early
The Insider Monkey team has completed processing the quarterly 13F filings for the March quarter submitted by the hedge funds and other money managers included in our extensive database.
Is ANAB Stock A Buy or Sell?
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don't make them change their opinion towards a...
5 Healthcare Stocks the Experts at Aquilo Capital Management Are Buying (1 Has Gained 88% This Month)
Marc Schneidman’s Aquilo Capital Management is a San Francisco-based, healthcare-focused long/short hedge fund that was founded in 2010.
Hedge Funds Are Very Bullish On AnaptysBio, Inc. (ANAB)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Hedge Fund Resource Center Billionaire Hedge Funds
